Symbols

BIAF

bioAffinity·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Ample Liquidity

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BIAF

Bioaffinity Technologies, Inc.

A company that develops proprietary noninvasive diagnostic tests and cancer therapeutics to diagnose early-stage cancer

Industry

Healthcare Equipment and Supplies

Established Date

03/26/2014

Listing Date

09/01/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.bioaffinitytech.com

Security Type

Common stock

Office address

3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217

Business

Introduction

BioAffinity Technologies, Inc., was incorporated as a Delaware corporation on March 26, 2014. The company develops non-invasive diagnostic tests that use flow cytometry and artificial intelligence-driven analysis for early-stage lung cancer and other respiratory diseases. Its main commercial testing product, CyPath Lung, is offered through its CAP-accredited laboratory subsidiary and is also advancing therapeutic research for cancer treatment.

Company Financials

EPS

BIAF has released its 2025 Q4 earnings. EPS was reported at -1.11, versus the expected -2.7, beating expectations. The chart below visualizes how BIAF has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BIAF has released its 2025 Q4 earnings report, with revenue of 1.59M, reflecting a YoY change of -27.85%, and net profit of -3.14M, showing a YoY change of -5.75%. The Sankey diagram below clearly presents BIAF's revenue sources and cost distribution.